approval
saveTAFINLAR (DABRAFENIB MESYLATE) — FDA approval
community read0 votes
Sponsor: NOVARTIS. Form: CAPSULE. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 26, 2026 · 193d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 26, 2026 · 193d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalApr 7, 2025 · 546d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalApr 7, 2025 · 546d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 19, 2025 · 565d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 19, 2025 · 565d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 7, 2025 · 577d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 7, 2025 · 577d ago
same company · ±60 days · 6
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 16, 2023
- approvalSpexotras: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalMar 16, 2023
- approvalSpexotras: MEKINIST (TRAMETINIB) — FDA approvalMar 16, 2023
- approvalZOLEDRONIC ACID — FDA approvalMar 7, 2023
- approvalinclisiran: LEQVIO (INCLISIRAN SODIUM) — FDA approvalFeb 17, 2023
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalMay 11, 2023
comments(0)
5-min edit window · permanent after that